Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation.
In clinical practices, solution of dorzolamide hydrochloride (DH) and timolol maléate (TM) is recommended for the treatment of glaucoma. However, low drug-contact time and poor ocular bioavailability of drugs due to drainage of solution, tear turnover and its dilution or lacrimation limits its uses. In addition, systemic absorption of TM may induce undesirable cardiovascular side effects. Chitosan (CS) is a polycationic biodegradable polymer which provides sustained and local delivery of drugs to the ocular sites. Hyaluronic acid (HA) also provides synergistic effect for mucoadhesion in association with chitosan. In the present study, hyaluronic acid modified chitosan nanoparticles (CS-HA-NPs) loaded with TM and DH were developed and characterized. The CS-HA-NPs were evaluated for size, shape, zeta potential, entrapment efficiency, and mucoadhesive strength. The in vitro release study was also performed in PBS pH 7.4. The ocular irritation potential of CS-HA-NPs was estimated using draize test on albino rabbits. A significant reduction in IOP level was obtained using CS-HA-NPs as compared to plain solution of drug and a comparable higher reduction in IOP level was observed as to CS-NPs. These results suggest that HA potentialy enhance the mucoadhesiveness and efficiency of CS-NPs and may be promising carrier for ocular drug delivery.
Wadhwa
Sheetu
S
Nanomedicine Research Centre, Department of Pharmaceutics, Indo-Soviet Friendship College of Pharmacy, Moga, Punjab, India.
Paliwal
Rishi
R
Paliwal
Shivani R
SR
Vyas
S P
SP
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000818:Animals; D001682:Biological Availability; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D048271:Chitosan / Q000737:chemistry*; D004337:Drug Carriers; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006820:Hyaluronic Acid / Q000737:chemistry*; D053758:Nanoparticles; D011817:Rabbits; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013999:Timolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D004337:Drug Carriers; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; D006820:Hyaluronic Acid; D048271:Chitosan; C062765:dorzolamide